Investigation of the role of SDHB inactivation in sporadic phaeochromocytoma and neuroblastoma
Open Access
- 26 October 2004
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 91 (10) , 1835-1841
- https://doi.org/10.1038/sj.bjc.6602202
Abstract
Germline mutations in the succinate dehydrogenase (SDH) (mitochondrial respiratory chain complex II) subunit B gene, SDHB, cause susceptibility to head and neck paraganglioma and phaeochromocytoma. Previously, we did not identify somatic SDHB mutations in sporadic phaeochromocytoma, but SDHB maps to 1p36, a region of frequent loss of heterozygosity (LOH) in neuroblastoma as well. Hence, to evaluate SDHB as a candidate neuroblastoma tumour suppressor gene (TSG) we performed mutation analysis in 46 primary neuroblastomas by direct sequencing, but did not identify germline or somatic SDHB mutations. As TSGs such as RASSF1A are frequently inactivated by promoter region hypermethylation, we designed a methylation-sensitive PCR-based assay to detect SDHB promoter region methylation. In 21% of primary neuroblastomas and 32% of phaeochromocytomas (32%) methylated (and unmethylated) alleles were detected. Although promoter region methylation was also detected in two neuroblastoma cell lines, this was not associated with silencing of SDHB expression, and treatment with a demethylating agent (5-azacytidine) did not increase SDH activity. These findings suggest that although germline SDHB mutations are an important cause of phaeochromocytoma susceptibility, somatic inactivation of SDHB does not have a major role in sporadic neural crest tumours and SDHB is not the target of 1p36 allele loss in neuroblastoma and phaeochromocytoma.Keywords
This publication has 47 references indexed in Scilit:
- SDHD mutation analysis in seven German patients with sporadic carotid body paraganglioma: one novel mutation, no Dutch founder mutation and further evidence that G12S is a polymorphismClinical Genetics, 2003
- Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell linesOncogene, 2002
- RASSF1A promoter region CpG island hypermethylation in phaeochromocytomas and neuroblastoma tumoursOncogene, 2001
- Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumoursOncogene, 2001
- Identification and characterization of a 500-kb homozygously deleted region at 1p36.2-p36.3 in a neuroblastoma cell lineOncogene, 2000
- Mitochondria and ApoptosisScience, 1998
- Mutations in the RET proto-oncogene and the von Hippel-Lindau disease tumour suppressor gene in sporadic and syndromic phaeochromocytomas.Journal of Medical Genetics, 1995
- Somatic mutations of the von Hippel — Lindau disease tumour suppressor gene in non-familial clear cell renal carcinomaHuman Molecular Genetics, 1994
- Mutations of the VHL tumour suppressor gene in renal carcinomaNature Genetics, 1994
- Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumoursHuman Molecular Genetics, 1994